SCHEMBL4704337

SCHEMBL4704337

CCC1Cc2nc3sc(C#N)c(N)c3cc2CC1C(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.53
ALDH1A1 P00352 11/20 0.53
MAPT P10636 10/20 0.53
LMNA P02545 2/20 0.53
HSD17B10 Q99714 4/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
ALOX15 P16050 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
XBP1 P17861 1/20 0.41
KMT2A Q03164 1/20 0.41
TP53 P04637 2/20 0.35
HPGD P15428 5/20 0.34
CYP2C19 P33261 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
RORC P51449 1/20 0.33
TSHR P16473 2/20 0.32
MAPK1 P28482 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4703109 0.85 KDM4E (0.56) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL22690991 0.78 MAPT (0.61) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL4704685 0.78 MAPT (0.61) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL13154843 0.76 KDM4E (0.65) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL13670442 0.74 MAPT (0.65) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL4704433 0.73 KDM4E (0.55) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL5997173 0.71 MAPT (0.61) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL4705401 0.71 POLB (0.37) KDM4EALDH1A1HSD17B10SMN1; SMN2ALOX15
SCHEMBL13154827 0.67 MAPT (0.46) KDM4EALDH1A1MAPTLMNAHSD17B10
SCHEMBL5996852 0.65 MAPT (0.44) KDM4EALDH1A1MAPTLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871776-A2 FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2008-01-02 EP disclosed
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity SCHERING CORPORATION 2006-11-02 US disclosed
WO-2006098961-A2 FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity KIFC1, KIF5B, KIF2C KDM4E 501/4885ALDH1A1 2371/4885MAPT 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.